Moderna, Inc. - NASDAQ:MRNA - Comprehensive analysis
Moderna's shares have experienced significant volatility, with investors initially overly optimistic in 2021 regarding the company's technological potential, followed by a more pessimistic outlook on its growth post-coronavirus. While we maintain modest expectations for sales of the firm's COVID vaccine after the substantial pandemic-driven demand in 2021 and 2022, we believe that Moderna's pipeline of mRNA-based vaccines and treatments is progressing swiftly across various therapeutic areas. Despite a decline in sales during 2023-2024 in anticipation of new product launches, we remain confident in the long-term sales trajectory of the company's diversified pipeline. We see strong validation of Moderna's technology in respiratory virus vaccines (with an RSV vaccine set to launch in 2024 and a COVID/flu combination approval anticipated in 2025), oncology (with a potential melanoma launch by 2027), and rare diseases (with possible accelerated approvals by 2026).
Free evaluation through quantitative algorithms Moderna, Inc. - NASDAQ:MRNA
Growth-Scoring Model Detail
Total Revenue Growth Over Prior Year | -52.75 | Market 1 Sector 5 |
Gross Profit Growth Over Prior Year | 0 | Market 0 Sector 0 |
EBITDA Growth Over Prior Year | 0 | Market 0 Sector 0 |
EBITA Growth Over Prior Year | 0 | Market 0 Sector 0 |
EBIT Growth Over Prior Year | 0 | Market 0 Sector 0 |
Earnings from Cont. Ops. Growth Over Prior Year | 0 | Market 0 Sector 0 |
Net Income Growth Over Prior Year | 0 | Market 0 Sector 0 |
Normalized Net Income Growth Over Prior Year | 0 | Market 0 Sector 0 |
Diluted EPS before Extra Growth Over Prior Year | 0 | Market 0 Sector 0 |
A/R Growth Over Prior Year | -59.87 | Market 1 Sector 5 |
Inventory Growth Over Prior Year | -42.08 | Market 1 Sector 2 |
PPE Net Growth Over Prior Year | 11.17 | Market 81 Sector 79 |
Total Assets Growth Over Prior Year | -23.25 | Market 2 Sector 18 |
Tangible Book Value Growth Over Prior Year | -21.43 | Market 8 Sector 31 |
Common Equity Growth Over Prior Year | -21.32 | Market 6 Sector 30 |
Cash from Ops. Growth Over Prior Year | 0 | Market 0 Sector 0 |
CAPEX Growth Over Prior Year | 48.7 | Market 94 Sector 85 |
Dividend per Share Growth Over Prior Year | 0 | Market 36 Sector 48 |
Levered Free Cash Flow Growth Over Prior Year | 0 | Market 0 Sector 0 |
Unlevered Free Cash Flow Growth Over Prior Year | 0 | Market 0 Sector 0 |
Profitability-Scoring Model Detail
Gross Margin % | -85.63 | Market 1 Sector 2 |
SG&A Margin % | 36.3 | Market 89 Sector 47 |
EBITDA Margin % | -116.07 | Market 1 Sector 6 |
EBITA Margin % | -121.91 | Market 1 Sector 6 |
EBIT Margin % | -121.91 | Market 1 Sector 7 |
Earnings from Cont. Ops Margin % | -110.04 | Market 1 Sector 8 |
Net Income Margin % | -110.04 | Market 1 Sector 8 |
Net Income Avail. for Common Margin % | -110.04 | Market 1 Sector 8 |
Normalized Net Income Margin % | -68.58 | Market 1 Sector 10 |
Levered Free Cash Flow Margin % | -95.41 | Market 1 Sector 10 |
Unlevered Free Cash Flow Margin % | -94.95 | Market 1 Sector 10 |
Return on Assets % | -15.14 | Market 1 Sector 48 |
Return on Capital % | -18.44 | Market 1 Sector 48 |
Return on Equity % | -28.77 | Market 2 Sector 56 |
Return on Common Equity % | -28.77 | Market 2 Sector 56 |
Total Asset Turnover | 0.2 | Market 18 Sector 42 |
